# 1st Quarter 2025 Results



## 1st Quarter 2025 Sales

**$21.9B**

Worldwide increased ▲ **2.4%**

Excluding the impact of translational currency

Stelara impacted results by ~(470) basis points

Worldwide increased ▲ **4.2%**[1]

**Diluted earnings per share (EPS)** **$4.54**

Includes the reversal of special charges

**Adjusted diluted earnings per share[1]**

**$2.77**

Worldwide Increased ▲ **2.2%**

"The power of Johnson & Johnson's uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance. During the quarter, we fortified our position as an innovation powerhouse with major advancements across our pipeline, including TREMFYA in IBD, RYBREVANT plus LAZCLUZE in non-small-cell lung cancer, and OTTAVA, our soft tissue surgical robotic system, and further enhanced our leading neuroscience portfolio with the completion of the Intra-Cellular Therapies acquisition."

**Joaquin Duato**
Chairman & Chief Executive Officer
Johnson & Johnson

## $13.9 billion — Worldwide Innovative Medicine sales

Innovative Medicine worldwide reported sales increased 2.3% or 4.2% operationally[2]. Stelara impacted results by ~(810)[2] basis points. Primary operational drivers:

- DARZALEX (daratumumab) injection for intravenous infusion 100 mg/5 mL, 400 mg/20 mL
- CARVYKTI (ciltacabtagene autoleucel)
- Xarelto rivaroxaban
- Tremfya (guselkumab)
- Simponi golimumab
- Erleada (apalutamide)
- Spravato (esketamine) nasal spray
- RYBREVANT (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL) + LAZCLUZE (lazertinib)

## $8.0 billion — Worldwide MedTech sales

MedTech worldwide reported sales increased 2.5% or 4.1% operationally[2]
Primary operational drivers:

- Shockwave
- Abiomed
- Wound Closure
- Contact Lenses
- Surgical Vision
- Trauma
- Biosurgery

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson's earnings release issued April 15, 2025, available at https://www.investor.jnj.com/financials/quarterly-results/default.aspx

[1] Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

[2] Non-GAAP measure; excludes the impact of translational currency.

Note: Values may be rounded

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forwardlooking statements, review the "Note to Investors Concerning Forward-Looking Statements" included in the Johnson & Johnson earnings release issued on April 15, 2025, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.

Johnson&Johnson